Related Experiment Video

Updated: Jun 15, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Role of anti-Her-2 therapy in bladder carcinoma

Alvaro Pinto Marín1, Enrique Espinosa Arranz, Andrés Redondo Sánchez

  • 1Medical Oncology Department, University Hospital La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain. alvaro_pinto_marin@hotmail.com

Journal of Cancer Research and Clinical Oncology
|March 10, 2010
PubMed

Insights

Advanced bladder cancer lacks effective treatments post-chemotherapy. Targeting HER2 (Human Epidermal growth factor Receptor 2) shows promise, with drugs like trastuzumab under investigation for urothelial neoplasms.

Area of Science:

  • Oncology
  • Urothelial Carcinomas
  • Molecular Targeted Therapy

Background:

  • Advanced bladder cancer has limited therapeutic options beyond first-line platinum-combination chemotherapy.
  • Tumor progression after initial treatment leads to a poor prognosis with no established standard therapy.
  • Targeted therapies have revolutionized cancer treatment, but none are currently approved for advanced bladder cancer.

Purpose of the Study:

  • To review the evidence on Human Epidermal growth factor Receptor 2 (HER2) determination in bladder cancer.
  • To assess HER2's influence on bladder carcinoma prognosis and the clinical development of anti-HER2 therapies.
  • To explore future research directions for HER2-targeted treatments in advanced bladder cancer.

Main Methods:

  • Review of published literature on HER2 assessment in bladder cancer.
  • Analysis of clinical trial data for anti-HER2 agents in urothelial neoplasms.
  • Evaluation of HER2's prognostic significance in bladder carcinoma.

Main Results:

  • HER2 amplification and/or overexpression occurs in bladder cancer and may impact prognosis.
  • Anti-HER2 drugs (e.g., trastuzumab, lapatinib) are being investigated in urothelial neoplasms.
  • No Phase III trials have yet evaluated anti-HER2 therapies specifically for bladder cancer.

Conclusions:

  • Targeting HER2 represents a potential therapeutic strategy for advanced bladder cancer.
  • Further clinical trials, particularly Phase III studies, are needed to establish the efficacy of anti-HER2 therapies.
  • Understanding HER2 status is crucial for developing personalized treatment approaches in bladder cancer.

More Related Videos

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...